ViiV licenses new HIV drug to Medicines Patent Pool
This article was originally published in Scrip
Executive Summary
After just two months of EU approval, and eight months after the US FDA gave it the green light, ViiV Healthcare's dolutegravir (Tivicay) is the subject of an agreement with the Medicines Patent Pool (MPP) to accelerate access to the HIV medicine in poorer countries.